SGN, Inc.

MCLEAN, VA · Founded 2011 · CIK 0001571747 · Biotech · Private

Small and large molecule pharmaceuticals

sgnnanopharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$3.8M
1 Form D · Mar 2013
163 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$3,839,814
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2135INVIVO THERAPEUTICS HOLDINGS CORP.—$9.3M
2136Richard Fisher——
2137PLEXYMER, INC.——
2138SGN, Inc.—$3.8M
2139NOVATARG, INC.——
2140Helix Alternative Technologies Inc.—$6.0M
2141ImmunoMolecular Therapeutics, Inc.—$11M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 6 related persons
  • Jack DaviesDirector
  • Karl LewisExecutive Officer
  • Jay RappaportDirector
  • Gene RiechersDirector
  • Jeffrey RossDirector · Executive Officer
  • Fred SchaufeldDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.